Results 81 to 90 of about 22,562,840 (346)

Increased Thrombogenicity is Associated With Coronary Microvascular Dysfunction in Patients With STEMI—A Proof‐of‐Concept Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Up to 50% of patients with ST‐segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) develop coronary microvascular dysfunction (CMD). Aims This study aims to assess whether a prothrombotic state of coronary blood, defined by thromboelastography (TEG), is associated with post ...
Roberto Scarsini, Denis Leonardi, Andrea Bottardi, Concetta Mammone, Leonardo Portolan, Caterina Butturini, Verdiana Galli, Francesco Della Mora, Alessandro Ruzzarin, Sara Pazzi, Anna Piccoli, Simone Fezzi, Domenico Tavella, Gabriele Pesarini, Leonardo Gottin, Flavio Ribichini   +15 more
wiley   +1 more source

In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A. [PDF]

, 2018
Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the factor VIII ( FVIII) gene leading to deficient blood coagulation. The current standard of care is frequent infusions of plasma-derived FVIII or recombinant B-domain-deleted ...
Farmer, Diana, Gao, Kewa, Kumar, Priyadarsini, Lankford, Lee, Pivetti, Christopher, Wang, Aijun, Wang, Chuwang   +6 more
core   +1 more source

The strategies of parents who tell their daughters about the possibility of being a haemophilia carrier

The Journal of Haemophilia Practice, 2023
Women who carry the haemophilia gene have a genetic risk of having a son with haemophilia, as well as the risk of abnormal bleeding; thus, there is an increasing interest in ‘carriers’ as subjects that potentially require medical support.
Nozaki Keiko, Yamazaki Akemi
doaj   +1 more source

Burden of mild haemophilia A: Systematic literature review

Haemophilia, 2019
Although the clinical manifestations of severe haemophilia A (HA) are well studied, the challenges, if any, of living with mild HA are not clearly delineated to date.
F. Peyvandi, F. Tavakkoli, D. Frame, J. Quinn, Benjamin Kim, A. Lawal, Mimi C. Lee, W. Wong   +7 more
semanticscholar   +1 more source

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

Clinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou, Rohit Rao, Monica E. Shapiro, Nessy Tania, Cody Herron, Cynthia J. Musante, Jim H. Hughes   +6 more
wiley   +1 more source

Von Willebrand Disease [PDF]

, 2017
Von Willebrand Disease (VWD) is a blood clotting disorder characterized by low levels of the Von Willebrand Factor (VWF) in the blood. VWF is functions to bind platelets and promote clotting of the blood when vascular injury occurs.
Misla David, Ramon
core   +2 more sources

THE IMPORTANCE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND TREATMENT OF MUSCULOSKELETAL PROBLEMS OF HAEMOPHILIA A [PDF]

Romanian Journal of Pediatrics, 2018
Haemophilia A, defined by a deficiency of clotting factor VIII, can cause bleeding in various locations, especially on muscles and joints. For these patients, ultrasonography plays a very important role in the monitoring and shaping of the replacement ...
Adriana Diaconu, Oana Rizea, Horatiu Vultur   +2 more
doaj   +1 more source

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
In hemophilia B, pharmacokinetic (PK)‐guided dosing of extended half‐life factor IX (EHL‐FIX) concentrates can secure targeted FIX exposure. Target FIX activity levels in plasma should be individually set primarily taking bleeding tendency into account, alongside the presence of target joints, physical activity, and preferred dosing schedules. In other
Sjoerd F. Koopman, Marjon H. Cnossen, Ron A.A. Mathot, on behalf of the OPTI‐CLOT study group and SYMPHONY consortium, S. H. Reitsma   +4 more
wiley   +1 more source

Health-related quality of life in children with haemophilia in China: a 4-year follow-up prospective cohort study

Health and Quality of Life Outcomes, 2019
Background Health-related quality of life (HRQoL) has been brought up for decades in haemophilia patients. However, no data to date are available about HRQoL in children with haemophilia using long-term follow up data.
Heng Zhang, Jie Huang, Xiaoyan Kong, Gaoxiang Ma, Yongjun Fang   +4 more
doaj   +1 more source

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an HMA/EMA Multistakeholder Workshop

Clinical Pharmacology &Therapeutics, EarlyView.
The Joint Heads of Medicines Agencies and European Medicines Agency's (HMA/EMA) big data initiative paves the way for better integration of real‐world data, including data from patient registries, into regulatory decisions on medicines. This article focuses on the outcome of a two‐day multistakeholder workshop organized by EMA in 2024, which explored ...
Kelly Plueschke, Carla Jonker, Hanna Kankanen, Thorsten Vetter, Bruno Sepodes, Lutz Naehrlich, Jan Hillert, Gracy Crane, Sabine Straus, Paolo Foggi, Simona Martin, Christina Kyriakopoulou, Peter Mol, Francesca Day, Kieran Breen, Neil Bennett, Mencia de Lemus Belmonte, Simon Bennett, Patrice Verpillat, Kit C. B. Roes, Ana Cochino, Franz Schaefer, Jesús María Hernández‐Rivas, Patricia McGettigan, Peter Arlett   +24 more
wiley   +1 more source